Stock Events

Stock Events

Corbus Pharmaceuticals 

$8.80
193
-$0.21-2.33% 19:59 Today

Statistics

Day High
9.12
Day Low
8.64
52W High
20.56
52W Low
7.12
Volume
15,395,337
Avg. Volume
-
Mkt Cap
163.04M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-1.9
-1.53
-1.15
-0.78
Expected EPS
-1.25876
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-78.54MNet Income

Analyst Ratings

39.00Average Price Target
The highest estimate is 52.00.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CRBP. It's not an investment recommendation.
Apple
35
AAPL
Microsoft
30
MSFT
Tesla
29
TSLA
Amazon
27
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Abbvie
ABBV
Mkt Cap438.31B
AbbVie has a strong portfolio in immunology and inflammatory diseases, overlapping with Corbus's therapeutic areas.
Gilead Sciences
GILD
Mkt Cap161.19B
Gilead Sciences has a broad focus on life-threatening diseases, including inflammatory disorders, making it a competitor in the same therapeutic space as Corbus.
AMGEN
AMGN
Mkt Cap196.12B
Amgen has a diverse biotechnological portfolio, including treatments for inflammatory diseases, competing with Corbus's market.
Bristol-Myers Squibb
BMY
Mkt Cap117.58B
Bristol Myers Squibb offers several products in the area of immune system modulation and inflammation, competing with Corbus's research and product development.
Pfizer
PFE
Mkt Cap137.76B
Pfizer has a wide range of products targeting inflammatory and autoimmune diseases, directly competing with Corbus's focus areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap69.67B
Regeneron Pharmaceuticals specializes in medicines for serious medical conditions, including inflammatory diseases, making it a competitor to Corbus.
Vertex Pharmaceuticals
VRTX
Mkt Cap123.19B
Vertex Pharmaceuticals invests in creating transformative medicines for people with serious diseases, including those related to inflammation, competing with Corbus's mission.
Incyte
INCY
Mkt Cap23.32B
Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics, including for inflammation, competing with Corbus.
Merck
MRK
Mkt Cap305.12B
Merck operates in various therapeutic areas, including immunology and inflammation, making it a competitor to Corbus Pharmaceuticals.

About

Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
Show more...
CEO
Dr. Yuval Cohen Ph.D.
Employees
36
Country
United States
ISIN
US21833P3010

Listings

MU
DE
337.MU
STU
DE
3371.STU
STU
DE
337.STU
MU
DE
3371.MU

0 Comments

Share your thoughts

FAQ

What is Corbus Pharmaceuticals stock price today?▼
The current price of CRBP is $8.80 USD — it has decreased by -2.33% in the past 24 hours. Watch Corbus Pharmaceuticals stock price performance more closely on the chart.
What is Corbus Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Corbus Pharmaceuticals stocks are traded under the ticker CRBP.
Is Corbus Pharmaceuticals stock price growing?▼
CRBP stock has fallen by -9.94% compared to the previous week, the month change is a +10.41% rise, over the last year Corbus Pharmaceuticals has showed a +2.11% increase.
What is Corbus Pharmaceuticals market cap?▼
Today Corbus Pharmaceuticals has the market capitalization of 163.04M
When is the next Corbus Pharmaceuticals earnings date?▼
Corbus Pharmaceuticals is going to release the next earnings report on August 11, 2026.
What were Corbus Pharmaceuticals earnings last quarter?▼
CRBP earnings for the last quarter are -1.23 USD per share, whereas the estimation was -1.22 USD resulting in a -0.78% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Corbus Pharmaceuticals revenue for the last year?▼
Corbus Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Corbus Pharmaceuticals net income for the last year?▼
CRBP net income for the last year is -78.54M USD.
How many employees does Corbus Pharmaceuticals have?▼
As of July 16, 2026, the company has 36 employees.
In which sector is Corbus Pharmaceuticals located?▼
Corbus Pharmaceuticals operates in the Health & Wellness sector.
When did Corbus Pharmaceuticals complete a stock split?▼
The last stock split for Corbus Pharmaceuticals was on February 14, 2023 with a ratio of 1:30.
Where is Corbus Pharmaceuticals headquartered?▼
Corbus Pharmaceuticals is headquartered in Norwood, United States.